June 2017

29 Jun

40

Positive Data from APL-2 Studies Show Rapid and Durable Improvements in LDH and Hemoglobin Levels in PNH

In All, Portfolio

Louisville, KY, June 29, 2017 – Apellis Pharmaceuticals, Inc. today provided an update on clinical outcomes in its two ongoing Phase 1b clinical trials with APL-2, a complement C3 inhibitor, in the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare, acquired,…

28 Jun

38

Groundbreaking Research Into Kinases Using CellOPTIQ From Clyde Biosciences

In All, Portfolio

Highlights from the publication include: Collaboration with AZ on kinase inhibitor induced cardiotoxicity Understanding E-C coupling is essential in kinase research CellOPTIQ® is the only single mechanistic screen providing insight into E-C coupling mechanism Observing the interplay between voltage, calcium transient and contractility is vital…

20 Jun

33

IGEM Therapeutics Completes Initial Closing of Series A Financing; Appoints CEO

In All, Portfolio

Raises £2 million from Epidarex Capital to progress pipeline of IgE antibody drug candidates to treat cancer IgE antibodies shown to offer greater efficacy than IgG comparator in cancer models Dr. Tim Wilson appointed Chief Executive Officer London, 20 June 2017 – IGEM Therapeutics (IGEM),…